Background The present review is part of the ESCMID Study Group for Infections in
Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and …

Eculizumab has opened new horizons in the treatment of complement-mediated disorders.
Prophylactic and immunization strategies against the risk of Nesseria spp. infections are …

Despite the success of desensitization protocols, antibody-mediated rejection (AMR)
remains a significant contributor to renal allograft failure in patients with donor-specific …

Background Atypical hemolytic uremic syndrome (HUS) is associated with high recurrence
rates after kidney transplant, with devastating outcomes. In late 2011, experts in France …

With the introduction of the complement C5-inhibitor eculizumab, a new era was entered for
patients with atypical hemolytic uremic syndrome (aHUS). Eculizumab therapy very …

Thrombotic microangiopathy (TMA) is a serious complication of transplantation that
adversely affects kidney transplant recipient and allograft survival. Post-transplant TMA is …

Background: Kidney transplantation in patients with atypical hemolytic uremic syndrome
(aHUS) is frequently complicated by recurrence, resulting in thrombotic microangiopathy in …

Thrombotic microangiopathy is a rare but serious complication that affects kidney transplant
recipients. It appears in 0.8–14% of transplanted patients and negatively affects graft and …

Thrombotic microangiopathy (TMA) is one of the most devastating sequalae of kidney
transplantation. A number of published articles have covered either de novo or recurrent …

Background The development of complement inhibitors has greatly improved the outcome of
patients with atypical hemolytic uremic syndrome (aHUS), making kidney transplantation a …